UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Approach to survivors of epithelial ovarian, fallopian tubal, or peritoneal carcinoma

Author
Linda R Duska, MD
Section Editors
Larissa Nekhlyudov, MD, MPH
Barbara Goff, MD
Don S Dizon, MD, FACP
Deputy Editors
Sadhna R Vora, MD
Sandy J Falk, MD, FACOG

INTRODUCTION

Ovarian cancer is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States. Epithelial ovarian carcinoma is the most common histologic type of ovarian cancer and is closely related to fallopian tubal and peritoneal carcinomas. These will be referred to as a single entity here, as epithelial ovarian carcinoma (EOC).

Five-year survival rates for stage III or IV EOC are <50 percent and <20 percent, respectively (table 1). However, in 2016 there were more than 230,000 EOC survivors in the United States and there are some long-term survivors of EOC [1].

Issues pertaining to survivorship in EOC are not well-studied. This may be due to the overall poor prognosis of women with ovarian cancer and smaller populations of affected individuals compared with patients with other cancers (eg, endometrial or breast cancer). Additionally, there are many studies of ovarian cancer survivors and their difficulties, but there are few data to guide management. Nevertheless, survivorship-related issues are important to address in this growing population of women.

The approach to survivors of EOC will be reviewed here. Related topics are discussed in detail separately, including:

Overview, diagnosis, and treatment:

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2017. | This topic last updated: Aug 21, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66:271.
  2. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983; 250:3072.
  3. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322:1021.
  4. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34.
  5. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95:105.
  6. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf (Accessed on July 19, 2017).
  7. Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.
  8. Fleming ND, Cass I, Walsh CS, et al. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 2011; 121:249.
  9. Rustin G, van der Burg M, Griffin C, et al. Early versus delayed treatment of relapsed ovarian cancer. Lancet 2011; 377:380.
  10. Rustin GJ. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol 2011; 22 Suppl 8:viii45.
  11. Limei Z, Yong C, Yan X, et al. Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. Int J Gynecol Cancer 2013; 23:598.
  12. Wenzel L, Huang HQ, Monk BJ, et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2005; 23:5605.
  13. von Gruenigen VE, Huang HQ, Gil KM, et al. A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. J Pain Symptom Manage 2010; 39:839.
  14. Joly F, Giffard B, Rigal O, et al. Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage 2015; 50:830.
  15. Wenzel LB, Donnelly JP, Fowler JM, et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology 2002; 11:142.
  16. Mirabeau-Beale KL, Kornblith AB, Penson RT, et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol 2009; 114:353.
  17. Ezendam NP, Pijlman B, Bhugwandass C, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol 2014; 135:510.
  18. Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 2007; 17:387.
  19. Mayerhofer K, Bodner-Adler B, Bodner K, et al. A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: a prospective study in patients with ovarian cancer. Anticancer Res 2000; 20:4051.
  20. Kudelka AP, Hasenburg A, Verschraegen CF, et al. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs 1998; 9:405.
  21. Hensley ML, Correa DD, Thaler H, et al. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol 2006; 102:270.
  22. Hess LM, Chambers SK, Hatch K, et al. Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. J Support Oncol 2010; 8:252.
  23. Correa DD, Zhou Q, Thaler HT, et al. Cognitive functions in long-term survivors of ovarian cancer. Gynecol Oncol 2010; 119:366.
  24. Hess LM, Huang HQ, Hanlon AL, et al. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 2015; 139:541.
  25. Ferguson RJ, Sigmon ST, Pritchard AJ, et al. A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer 2016; 122:1782.
  26. Asher A, Myers JS. The effect of cancer treatment on cognitive function. Clin Adv Hematol Oncol 2015; 13:441.
  27. Newell S, Sanson-Fisher RW, Girgis A, Ackland S. The physical and psycho-social experiences of patients attending an outpatient medical oncology department: a cross-sectional study. Eur J Cancer Care (Engl) 1999; 8:73.
  28. Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998; 12:369.
  29. Liavaag AH, Dørum A, Fosså SD, et al. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol 2007; 25:2049.
  30. Payne JK. The trajectory of fatigue in adult patients with breast and ovarian cancer receiving chemotherapy. Oncol Nurs Forum 2002; 29:1334.
  31. Ahlberg K, Ekman T, Gaston-Johansson F. Fatigue, psychological distress, coping resources, and functional status during radiotherapy for uterine cancer. Oncol Nurs Forum 2005; 32:633.
  32. Donovan HS, Ward S. Representations of fatigue in women receiving chemotherapy for gynecologic cancers. Oncol Nurs Forum 2005; 32:113.
  33. Donnelly CM, Blaney JM, Lowe-Strong A, et al. A randomised controlled trial testing the feasibility and efficacy of a physical activity behavioural change intervention in managing fatigue with gynaecological cancer survivors. Gynecol Oncol 2011; 122:618.
  34. Teng FF, Kalloger SE, Brotto L, McAlpine JN. Determinants of quality of life in ovarian cancer survivors: a pilot study. J Obstet Gynaecol Can 2014; 36:708.
  35. Diaz JP, Tew WP, Zivanovic O, et al. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol 2010; 116:335.
  36. Rose PG, Piver MS. Intestinal perforation secondary to paclitaxel. Gynecol Oncol 1995; 57:270.
  37. Wenzel LB, Huang HQ, Armstrong DK, et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:437.
  38. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365:2473.
  39. Fitch M, Gray RE, Franssen E. Perspectives on living with ovarian cancer: young women's views. Can Oncol Nurs J 2000; 10:101.
  40. Fitch MI, Gray RE, Franssen E. Perspectives on living with ovarian cancer: older women's views. Oncol Nurs Forum 2001; 28:1433.
  41. Lakusta CM, Atkinson MJ, Robinson JW, et al. Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol 2001; 81:490.
  42. Duska LR, Chang YC, Flynn CE, et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer 1999; 85:2623.
  43. Plaxe SC, Braly PS, Freddo JL, et al. Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol 1993; 81:651.
  44. Green JA. Early ovarian cancer--time for a rethink on stage? Gynecol Oncol 2003; 90:235.
  45. Sun CC, Ramirez PT, Bodurka DC. Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 2007; 4:18.
  46. Levin AO, Carpenter KM, Fowler JM, et al. Sexual morbidity associated with poorer psychological adjustment among gynecological cancer survivors. Int J Gynecol Cancer 2010; 20:461.
  47. Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol 2004; 22:881.
  48. Liavaag AH, Dørum A, Bjøro T, et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol 2008; 108:348.
  49. Hopkins TG, Stavraka C, Gabra H, et al. Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation. Climacteric 2015; 18:94.
  50. Bober S, Blackmom JE, Recklitis CJ, Wright A. BA-1. Sexual therapy and rehabilitation after treatment for ovarian cancer (START-OC): Preliminary results from a brief psychosexual intervention. Presented at the 8th Biennial Cancer Survivorship Research Conference, Washington, DC, 2016.
  51. Barton D, La Vasseur B, Loprinzi C, et al. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 2002; 29:33.
  52. Kimmick GG, Lovato J, McQuellon R, et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006; 12:114.
  53. Pergialiotis V, Pitsouni E, Prodromidou A, et al. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause 2016; 23:335.
  54. Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol 2015; 139:355.
  55. Eeles RA, Morden JP, Gore M, et al. Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. J Clin Oncol 2015; 33:4138.
  56. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999; 86:1013.
  57. Power L, Lefas G, Lambert P, et al. Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival. Obstet Gynecol 2016; 127:837.
  58. Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015; 385:1835.
  59. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991; 68:269.
  60. Kommoss F, Pfisterer J, Thome M, et al. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992; 47:317.
  61. Danforth KN, Tworoger SS, Hecht JL, et al. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 2007; 96:151.
  62. Lipkowitz S, Kohn EC. To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer. J Clin Oncol 2015; 33:4127.
  63. Norton TR, Manne SL, Rubin S, et al. Prevalence and predictors of psychological distress among women with ovarian cancer. J Clin Oncol 2004; 22:919.
  64. Shinn EH, Taylor CL, Kilgore K, et al. Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients. Palliat Support Care 2009; 7:299.
  65. Cain EN, Kohorn EI, Quinlan DM, et al. Psychosocial reactions to the diagnosis of gynecologic cancer. Obstet Gynecol 1983; 62:635.
  66. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 2000; 78:302.
  67. Clevenger L, Schrepf A, Degeest K, et al. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer 2013; 119:3234.
  68. von Gruenigen VE, Huang HQ, Gil KM, et al. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer 2009; 115:4857.
  69. Hipkins J, Whitworth M, Tarrier N, Jayson G. Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. Br J Health Psychol 2004; 9:569.
  70. Hodgkinson K, Butow P, Fuchs A, et al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes. Gynecol Oncol 2007; 104:381.
  71. Gonçalves V, Jayson G, Tarrier N. A longitudinal investigation of posttraumatic stress disorder in patients with ovarian cancer. J Psychosom Res 2011; 70:422.
  72. McKenzie H, Crouch M. Discordant feelings in the lifeworld of cancer survivors. Health (London) 2004; 8:139.
  73. Shand LK, Brooker JE, Burney S, et al. Symptoms of posttraumatic stress in Australian women with ovarian cancer. Psychooncology 2015; 24:190.
  74. Fitch MI, Steele R. Identifying supportive care needs of women with ovarian cancer. Can Oncol Nurs J 2010; 20:66.
  75. Browall M, Carlsson M, Horvath GG. Information needs of women with recently diagnosed ovarian cancer--a longitudinal study. Eur J Oncol Nurs 2004; 8:200.
  76. Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002; 3:529.
  77. Penson RT, Dignan F, Seiden MV, et al. Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol 2004; 94:427.
  78. Lockwood-Rayermann S. Survivorship issues in ovarian cancer: a review. Oncol Nurs Forum 2006; 33:553.
  79. Howell D, Fitch MI, Deane KA. Impact of ovarian cancer perceived by women. Cancer Nurs 2003; 26:1.
  80. Howell D, Fitch MI, Deane KA. Women's experiences with recurrent ovarian cancer. Cancer Nurs 2003; 26:10.
  81. Beesley VL, Price MA, Butow PN, et al. Physical activity in women with ovarian cancer and its association with decreased distress and improved quality of life. Psychooncology 2011; 20:1161.